RxDoctor Payments Data

Lindi Binder, PA

Physician Assistant · Moberly, MONPI 1538442314

Payments from drug & device makers

$973in general payments, 2019–2025

Across 32 payments — averaging $30.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$438
  • Abbott$175
  • Boehringer Ingelheim$81
  • AstraZeneca$38
  • Lundbeck LLC$38
  • Amgen$36
  • plus $167 from 8 others

What the payments were for

  • Food & beverage$81083%
  • Education$16217%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$973 in reported general payments places this provider in the 70th percentile of 1,380 physician assistant providers in Missouri.

See all physician assistant providers in Missouri

Medicare billing

Part B allowed, 2024
$18,645
Medicare patients
113
Services billed
332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin157$156,856
OzempicSemaglutide123$134,677
TrulicityDulaglutide82$107,077
MounjaroTirzepatide78$85,361
Tresiba Flextouch U-100Insulin Degludec71$73,893
FarxigaDapagliflozin Propanediol76$69,782
Humulin R U-500 KwikpenInsulin Regular, Human28$69,005
JanuviaSitagliptin Phosphate55$54,064
Humalog Kwikpen U-100Insulin Lispro148$53,343
Lantus SolostarInsulin Glargine,hum.Rec.Anlog309$53,079
Novolog FlexpenInsulin Aspart105$36,218
Humalog Kwikpen U-200Insulin Lispro37$35,184
Tresiba Flextouch U-200Insulin Degludec43$29,717
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog21$29,603
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog40$29,549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro, Humulin 70-30$33$219,233271 claims
Novo NordiskOzempic, Rybelsus, Novolog$32$162,053163 claims
Boehringer IngelheimJardiance$81$156,856157 claims
AstraZenecaFarxiga$38$69,78276 claims
MerckJanuvia$17$54,06455 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,380 physician assistant providers in Missouri.

Other physician assistant in Moberly

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →